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Objectives. The echocardiographic contrast-enhancing effects
and safety profile of ALBUNEX (a suspension of air-filled albu-
min microspheres) were compared with the new contrast agent
OPTISON (formerly FS069: a suspension of albumin micro-
spheres containing the gas perfluoropropane) in 203 patients with
inadequate noncontrast echocardiograms.
Background. The efficacy of ALBUNEX has been limited by its
short duration of action. By using perfluoropropane instead of air
within the microsphere, its duration of action is increased.
Methods. Each patient received ALBUNEX (0.8 and
0.22 mL/kg) and OPTISON (0.2, 0.5, 3.0, and 5.0 mL) on separate
days a minimum of 48 hours apart. Echocardiograms were
evaluated for increase in left ventricular (LV) endocardial border
length, degree of LV opacification, number of LV endocardial
border segments visualized, conversion from a nondiagnostic to a
diagnostic echocardiogram, and duration of contrast enhance-
ment. A thorough safety evaluation was conducted.
Results. Compared with ALBUNEX, OPTISON more signifi-
cantly improved every measure of contrast enhancement. OPTI-
SON increased well-visualized LV endocardial border length by
6.0 6 5.1, 6.9 6 5.4, 7.5 6 4.7, and 7.6 6 4.8 cm, respectively, for
each of the four doses, compared with only 2.2 6 4.5 and 3.4 6
4.6 cm, respectively, for the two ALBUNEX doses (p < 0.001).
100% LV opacification was achieved in 61%, 73%, 87%, and 87% of
the patients with the four doses of OPTISON, but in only 16% and
36% of the patients with the two ALBUNEX doses (p < 0.001).
Conversion of nondiagnostic to diagnostic echocardiograms with
contrast occurred in 74% of patients with the optimal dose of
OPTISON (3.0 mL) compared with only 26% with the optimal
dose of ALBUNEX (0.22 mL/kg) (p < 0.001). The duration of
contrast effect was also significantly greater with OPTISON than
with ALBUNEX. In a subset of patients with potentially poor
transpulmonary transit of contrast (patients with chronic lung
disease or dilated cardiomyopathy), OPTISON more significantly
improved the same measures of contrast enhancement compared
with ALBUNEX and did so to the same extent as in the overall
population. Side effects were similar and transient with the two
agents.
Conclusion. OPTISON appears to be a safe, well-tolerated
echocardiographic contrast agent that is superior to ALBUNEX.
(J Am Coll Cardiol 1998;32:746–52)
©1998 by the American College of Cardiology
Since its introduction, ALBUNEX has had only partial success
as an echocardiographic contrast agent (1–5). Unfortunately,
when given intravenously, its power to enhance left ventricular
(LV) structures has been limited by its relatively short duration
of action. ALBUNEX consists of microspheres prepared by
the sonication of human albumin in the presence of air.
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OPTISON, formerly known as FS069, was developed to
stabilize these microspheres and prolong their duration of
action. To achieve this, a 1% solution of human albumin is
sonicated in the presence of an inert gas, perfluoropropane.
Like ALBUNEX, the product is fully manufactured and is
ready for injection after simple resuspension. Preliminary
studies have demonstrated the improved contrast effect and
increased duration of OPTISON (6,7). We report here the first
multicenter clinical trial of OPTISON. Its efficacy and safety
are compared with ALBUNEX in patients with suboptimal
routine echocardiograms.
Methods
Study design. This study was a prospective, multicenter
comparison of two intravenous echocardiographic contrast
agents, ALBUNEX and OPTISON. The principal objectives of
the study were to compare the contrast-induced increase in LV
endocardial border delineation, degree of LV chamber opaci-
fication, number of LV endocardial border segments visual-
ized, conversion from a nondiagnostic to diagnostic echocar-
diogram, and duration of contrast effect of the two agents in
patients with poorly defined noncontrast echocardiograms.
The safety and tolerability of the two agents were also com-
pared.
Patient selection. Patients were selected from those under-
going routine diagnostic echocardiography at 14 investigative
sites. To be included, patients had to have poor LV endocar-
dial border delineation, i.e., at least two of six endocardial
segments in the apical four-chamber view not adequately
visualized. The study was approved by the human subjects
review committee at the participating institutions. Signed
informed consent was obtained for each patient prior to
enrollment in the study. For female patients of child-bearing
potential, a negative serum pregnancy test within 24 h of
testing was required. Exclusion criteria were: known or sus-
pected hypersensitivity to blood, blood products or albumin;
pregnancy or lactation; recent cerebrovascular event or tran-
sient ischemic attack within the previous 6 months; confine-
ment to an intensive care unit or on a mechanical ventilator;
New York Heart Association class IV congestive heart failure;
LV ejection fraction ,20%; or severe liver disease.
From this study population, a subgroup of patients was
identified who had dilated cardiomyopathy or chronic pulmo-
nary disease, conditions known to impair the transpulmonary
transit of echo contrast agents. The study design required that
25% of the patients enrolled fall into this subgroup. Patients in
this impaired function group were those with an LV ejection
fraction of 20–40% or a history of clinically significant asthma,
chronic bronchitis, emphysema, bronchiectasis, or pulmonary
hypertension. The demonstration of safety of new contrast
agents is important in this population. There are theoretical
concerns about pulmonary microcirculatory compromise with
echo contrast agents in these patients.
Contrast agents. ALBUNEX is a suspension of air-filled
microspheres with a mean concentration of 3.0–5.0 3 108
microspheres/mL and a mean diameter of 3.0–5.0 mm. OPTI-
SON is a suspension of perfluoropropane-filled albumin mi-
crospheres with a mean concentration of 5.0–8.0 3 108
microspheres/mL and a mean diameter of 2.0–4.5 mm. Like
ALBUNEX, OPTISON is completely manufactured and is
prepared for injection by rotating the vial for a few seconds.
Each patient received ALBUNEX and OPTISON on separate
days at least 48 h apart. The sequence of contrast administra-
tion was randomized: half of the patients received ALBUNEX
and half received OPTISON on the first test session.
Two-dimensional echocardiography. Standard, continu-
ous, fundamental, two-dimensional echocardiography was
used. Prior to baseline imaging, ultrasound settings for each
patient were optimized for the apical four-chamber view with
the assistance of a grey-scale phantom (ATS Laboratories,
Inc.). Once the clearest image of the phantom was obtained,
the ultrasound settings for each patient were maintained
throughout the testing sessions. For ALBUNEX, the apical
four-chamber view was utilized. If feasible, the apical two-
chamber and parasternal short axis and long axis views were
also obtained after contrast injection. For OPTISON, the
apical four-chamber, apical two-chamber, and parasternal
short and long axis views were used throughout. All imaging
was recorded on videotape (Fig. 1).
Image analysis. Echocardiograms were reviewed by a cen-
tral core laboratory (Georgetown University Medical Center)
blinded to patient history, contrast agent, and dose. All
observations were made at baseline and after each dose of
OPTISON and ALBUNEX following clearance of attenua-
tion. LV endocardial border length, endocardial border delin-
eation by segment, LV opacification, and diagnostic yield were
the parameters assessed in a blinded manner by the core lab
and are reported below. With the exception of LV endocardial
border length and diagnostic yield, each observation was also
made by the individual investigators in an unblinded manner
for comparison purposes. The duration of contrast effect was
assessed by the investigators only and is reported below.
LV endocardial border length. The apical four-chamber
view was digitized off-line by a commercially available imaging
system (Nova Microsonics Image Vue). Endocardial length
was obtained by measuring and summing those segments that
were well visualized. The increase in well-visualized endocar-
dial border length due to each agent dose compared with
noncontrast was calculated for systole and diastole.
LV endocardial border delineation by segment. The apical
four-chamber view was divided into six segments. Each seg-
ment was graded visually from the videotape. A qualitative
scale was used as follows: A 5 not well delineated; B 5
average delineation; C 5 good delineation; and D 5 excellent
Abbreviations and Acronyms
ECG 5 electrocardiogram
LV 5 left ventricular
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delineation. The proportion of patients whose endocardial
delineation improved $1 segment at end-diastole (from grade
A to grade B, C or D) was calculated for each agent dose.
LV chamber opacification. Visual assessment from the vid-
eotape images of LV peak filling was graded according to the
following qualitative scale: 0 5 none (0% LV filling); 1 5 faint
contrast (33% LV filling); 2 5 intermediate filling (67% LV
filling); and 3 5 full LV chamber opacification (100% LV
filling). The proportion of patients with each grade of LV
filling was calculated for each agent and dose, at systole, and
diastole.
Duration of contrast. From the imaging protocol, each
investigator was asked to calculate the duration of clinically
useful contrast effect for each agent dose.
Diagnostic yield. The rate of conversion from a nondiag-
nostic to a diagnostic echocardiogram with contrast was as-
sessed. Patients were considered to have a nondiagnostic
noncontrast echocardiogram if the apical four-chamber view
had a minimum of four of six segments graded as “A” (not well
visualized) at end-diastole. Studies were determined to have
become diagnostic after contrast if they improved to five or six
segments judged as visualized (graded as B, C, or D).
Safety and tolerability. At the time of enrollment into the
study, a detailed clinical history was obtained from each
patient. A physical examination, 12-lead electrocardiogram
(ECG), vital signs, urinalysis, creatine phosphokinase isoen-
zymes, chemistry panel, complete blood count, prothrombin,
and partial thromboplastin times were also obtained. These
parameters, along with symptom notation, were repeated after
each set of contrast agent administrations and again at 48 h
poststudy. Throughout each testing session, oxygen saturation,
vital signs, and ECG rhythm recordings were made. The onset,
severity, duration of adverse events, and their possible rela-
tionship to each agent were noted.
Statistical analysis. LV endocardial border length was
analyzed as a two-way ANOVA with factors of protocol and
agent/dose level. Tukey-adjusted contrasts on comparisons
between the two ALBUNEX doses and all four OPTISON
doses were performed. Proportion of patients converting from
nondiagnostic to diagnostic, improving in one or more seg-
ments, with .67% filling and with .100% LV filling were all
analyzed by Chi-square test. Since these were all highly statis-
tically significant (p , 0.001 for all), pair-wise comparisons
between the two ALBUNEX doses and all four OPTISON
doses were made with Fisher’s exact tests and a Bonferroni
correction. For each parameter reported, the sample size
varied slightly. This occurred because either the baseline or
contrast image could not be read due to poor image quality or
technical errors in image acquisition. Data are reported as
mean 6 standard deviation or number and percent of patients,
and represent the core lab analysis unless otherwise stated.
Results
Patient population. A total of 203 patients were enrolled in
the study (Table 1). Of these, 74 (37%) had either dilated
cardiomyopathy or chronic lung disease (impaired function
group). Seven patients received only one contrast agent. Three
patients received OPTISON on the first day but did not return
for ALBUNEX on the second day: one for bad weather
conditions, another withdrew without a reason, and one with-
Figure 1. Apical four-chamber views (end-diastole on left, end-systole
on right) from a single patient. Top, Before contrast, there is poor LV
endocardial border definition. Middle, After injection of 0.22 mg/kg of
ALBUNEX, there is minimal improvement in LV endocardial border
delineation and faint LV chamber opacification in diastole. In systole,
there is almost no contrast effect. Bottom, After injection of 0.5 mL of
OPTISON, there is 100% LV chamber opacification and almost
complete endocardial border delineation in both diastole and systole.
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drew on the advice of a family member. Four patients received
ALBUNEX on the first day but did not return for OPTISON
on the second day: one for intravenous access problems, one
for chest pain the evening after ALBUNEX injection, one for
pneumonia complicating chronic lung disease 48 h after receiv-
ing ALBUNEX, and another for emergency coronary bypass
surgery 5 d after ALBUNEX administration. None of these
problems were considered related to ALBUNEX by the inves-
tigators.
LV endocardial border length. For all patients, the in-
crease in LV endocardial border length at end-diastole (Fig.
2A) was greater with each dose of OPTISON (6.0 6 5.1, 6.9 6
5.4, 7.5 6 4.7, 7.6 6 4.8 cm) than with each dose of ALBUNEX
(2.2 6 4.5, 3.4 6 4.6 cm), p , 0.001. Similarly, in the impaired
function group, end-diastolic LV endocardial border length
increased more with each OPTISON dose (6.2 6 5.4, 6.6 6 6.7,
7.8 6 5.4, 8.0 6 5.4 cm) than with each ALBUNEX dose
(1.2 6 4.5, 2.8 6 4.4 cm), p , 0.001. End-systolic increases in
LV endocardial border length for all patients (Fig. 2B) were
also greater with each dose of OPTISON (3.5 6 4.6, 4.5 6 4.9,
4.8 6 4.6, 5.4 6 4.6 cm) than for each dose of ALBUNEX
(0.8 6 3.8, 1.4 6 3.8), p , 0.001. Again, in the impaired
function group, end-systolic LV endocardial border length
increased more with OPTISON (3.8 6 5.0, 5.2 6 5.8, 5.1 6 5.2,
6.7 6 4.7 cm) than with ALBUNEX (0.5 6 3.9, 1.6 6 4.0 cm)
p , 0.001.
LV endocardial delineation by segment. When endocardial
delineation was evaluated by segment, the percentage of all
patients improving by $1 segment was higher for each dose of
OPTISON (81% [154/191], 90% [172/192], 93% [177/190],
94% [174/186]) than for either dose of ALBUNEX (64%
[124/195], 74% [142/193]), p , 0.001. In the impaired function
group, improvement in segment delineation was noted in more
OPTISON patients (74% [51/69], 87% [61/70], 94% [65/69],
94% [62/66]) than in ALBUNEX patients (59% [41/70], 77%
[54/70]), p , 0.001 for each comparison except for ALBUNEX
0.08 mL/kg versus OPTISON 0.2 mL, p , 0.01; ALBUNEX
0.22 mL/kg versus OPTISON 0.2 mL, p 5 NS; ALBUNEX
0.22 mL/kg versus OPTISON 0.5 mL, p , 0.01.
LV opacification of 100%. Full LV opacification at end-
diastole (Fig. 3A) was achieved by a greater percentage of all
patients with each of the four doses of OPTISON (61%
[112/183], 73% [133/181], 87% [158/181], 87% [89/102]) than
with each of the two doses of ALBUNEX (16% [16/100], 36%
[68/187]), p , 0.001. Similarly, in the impaired function group,
a higher proportion of patients with OPTISON (58% [40/69],
71% [46/65], 87% [59/68], 83% [30/36]) attained complete LV
opacification compared with ALBUNEX (5% [2/37], 20%
[14/71]), p , 0.001. At end-systole (Fig. 3B), OPTISON again
produced full LV opacification in a higher percentage of all
patients (48% [87/183], 59% [107/181], 69% [125/181], 75%
[77/102]) than did ALBUNEX (7% [7/100], 9% [16/187]), p ,
0.001. In the impaired function group, OPTISON also
achieved complete LV opacification in more patients (46%
[32/69], 62% [40/65], 79% [54/68], 75% [27/36]) than did
ALBUNEX (3% [1/37], 4% [3/71]), p , 0.001.
LV opacification of >67%. This level of LV opacification at
end-diastole (Fig. 4A) was achieved in a higher percentage of
all patients with each of the four doses of OPTISON (81%
[148/183], 90% [163/181], 94% [171/181], 95% [97/102]) than
with either of the two doses of ALBUNEX (41% [41/100], 56%
[104/187]), p , 0.001. Similarly, in the impaired function
Table 1. Patient Characteristics (n 5 203)
Age (yr) 59 6 13
Male 161 (79)
Hypertension 118 (58)
Diabetes mellitus 63 (31)
Myocardial infarction 81 (40)
PTCA 33 (16)
CABG 43 (21)
Valvular disease 29 (14)
Congestive heart failure 66 (33)
Dilated cardiomyopathy 47 (23)
Chronic lung disease 35 (17)
Data are mean 6 SD or numbers of patients (%). CABG, coronary artery
bypass graft; PTCA, percutaneous transluminal coronary angioplasty.
Figure 2. A, Increase in LV endocardial border length at end-diastole
after the two doses of ALBUNEX (ALB) and the four doses of
OPTISON (OPT). Open bars, all patients; filled bars, impaired
function group. Doses of ALBUNEX in mL/kg, OPTISON in mL.
*p , 0.001 for each dose of OPTISON versus each dose of ALBU-
NEX. B, Increase in LV endocardial border length at end-systole.
Abbreviations and symbols as in A.
749JACC Vol. 32, No. 3 COHEN ET AL.
September 1998:746–52 OPTISON: A NEW ECHO CONTRAST AGENT
group, a higher proportion of patients with OPTISON (72%
[50/69], 85% [55/65], 94% [64/68], 94% [34/36]) attained this
degree of LV opacification compared with ALBUNEX (27%
[10/37], 35% [25/71]), p , 0.001. At end-systole (Fig. 4B),
OPTISON produced this level of LV opacification in a higher
percentage of all patients (60% [110/183], 73% [133/181], 81%
[147/181], 83% [85/102]) than did ALBUNEX (10% [10/100],
14% [26/187]), p , 0.001. In the impaired function group,
OPTISON attained this degree of LV opacification in more
patients (58% [40/69], 74% [48/65], 85% [58/68], 81% [29/36])
than did ALBUNEX (5% [2/37], 7% [5/71]), p , 0.001.
Diagnostic yield. The rate of conversion from a nondiag-
nostic to a diagnostic echocardiogram was evaluated with each
dose of contrast agent judged to be the most efficacious
(3.0 mL with OPTISON and 0.22 mL/kg with ALBUNEX)
based on the endocardial border length and LV opacification
analyses. The core laboratory identified 85 OPTISON patients
and 85 ALBUNEX patients who were considered to have
nondiagnostic baseline studies. Among all patients, a higher
percentage of the OPTISON studies (74%, 63/85) converted to
diagnostic echocardiograms compared with ALBUNEX (26%,
22/85), p , 0.001. Similarly, in the impaired function patients,
there were more conversions with OPTISON (75%, 30/40)
than with ALBUNEX (12%, 5/41), p , 0.001.
Duration of contrast. The duration of clinically useful
contrast effect was greater for all patients with each dose of
OPTISON (1.7 6 1.3, 2.4 6 1.8, 4.3 6 2.5, and 5.2 6 3.3 min)
than with each dose of ALBUNEX (0.6 6 0.6 and 0.8 6
0.7 min), p , 0.001.
Investigators’ assessments. Left ventricular opacification
and LV endocardial delineation by segment were evaluated by
the investigators as well as the core lab. The investigators’
assessments related closely to those of the core lab. In response to
the questionnaire regarding diagnostic confidence, investigators
thought ALBUNEX produced a diagnostic study in 45% (92/203)
of patients, whereas OPTISON was thought to produce a diag-
nostic study in 87% (176/203). Overall, investigators preferred
OPTISON over ALBUNEX in 97% (184/203) of patients.
Side effects. Among all patients, there were no clinically
significant changes in physical examination, vital signs, or ECG
with either OPTISON or ALBUNEX. In particular, there were
no significant changes in the heart rate, blood pressure, or
oxygen saturation in the impaired function group. Five patients
had mild decreases in oxygen saturation (mean decrease 8.0 6
0.7%): four with OPTISON and one with ALBUNEX. These
episodes were asymptomatic, transient, and resolved sponta-
neously. Side effects believed to be related to each agent are
Figure 3. A, 100% LV opacification at end-diastole. Pts, Patients.
Other abbreviations and symbols as in Figure 2A. B, 100% LV
opacification at end-systole. Abbreviations and symbols as in Figures
2A and 3A.
Figure 4. A, $67% LV opacification at end-diastole. Abbreviations
and symbols as in Figure 2A and 3A. B, $67% LV opacification at
end-systole. Abbreviations and symbols as in Figure 2A and 3A.
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shown in Table 2. There were no significant differences in side
effects between the two agents. None required treatment.
Discussion
This is the first multicenter clinical trial of OPTISON, a new
generation echocardiographic contrast agent. Its superiority
over ALBUNEX was demonstrated with continuous, funda-
mental imaging.
Characteristics of OPTISON. While ALBUNEX has
achieved some success as an ultrasound contrast agent (1–5),
its clinical usefulness has been limited by its relatively short
duration of contrast effect. ALBUNEX consists of albumin
microspheres filled with air, which in turn consists mainly of
oxygen and nitrogen. Graham’s Law states that the rate of
diffusion of gases is inversely proportional to the square root of
their molecular weights (8). Because oxygen and nitrogen have
low molecular weights (32 and 28 g/mol, respectively), they
easily diffuse out of the albumin microspheres. They are also
readily soluble in blood, another factor causing them to escape
from the microspheres. As the gases escape, the microspheres
become smaller. As particle size is the principal determinant of
ultrasound backscatter (9), the contrast effect diminishes as
microsphere size decreases. To obviate this, gases with less
diffusivity and less solubility in blood have been explored for
use with contrast agents (10,11). OPTISON is produced by the
sonication of a 1% solution of human albumin in the presence
of perfluoropropane, an inert gas approved by the FDA for use
in ophthalmologic surgery (12). Its high molecular weight (188
g/mol) makes it less diffusable than air. It is also less soluble in
blood. This significantly stabilizes microsphere size. As a result,
more microspheres survive the transit through the pulmonary
circulation for delivery to the left heart. In addition, higher
concentrations of microspheres in itself is protective against
destruction by ultrasound (13–15). The higher concentration of
microspheres reaching the left heart is responsible for the
increased contrast effect of OPTISON.
Efficacy. For all patients, OPTISON was significantly supe-
rior to ALBUNEX in all measures of contrast enhancement,
including increase in LV endocardial border length, LV opaci-
fication, endocardial segment delineation, diagnostic yield, and
duration of contrast. It should be emphasized that the patients
in this study had incomplete endocardial depiction on their
routine echocardiograms. Despite selecting only patients with
technically difficult images, OPTISON was able to improve LV
opacification such that 87% of patients had 100% LV opaci-
fication at end-diastole. This degree of LV filling with OPTI-
SON occurred in over three times the number of patients
compared with ALBUNEX. As a result of improved endocar-
dial border delineation and LV opacification, the investigators
reported a greater sense of diagnostic confidence with OPTI-
SON than with ALBUNEX.
Impaired function group. It has been shown previously
that patients with reduced forward cardiac output, such as
those with LV systolic dysfunction or pulmonary hypertension,
have diminished LV opacification with ALBUNEX (16,17). It
has been proposed that the reduced cardiac output causes a
delay in the transpulmonary transit of contrast. This causes
prolonged exposure of the microspheres to ultrasound and
ultrasound-induced microsphere destruction as well as more
time for diffusion of gas out of the microspheres with conse-
quent microsphere shrinkage (16,17).
In the present study, 74 patients had chronic lung disease or
dilated cardiomyopathy. As expected, there was decreased
contrast effect with ALBUNEX in these patients. OPTISON,
however, maintained its contrast effect in this subgroup. In
fact, there was a trend toward increased LV endocardial
border delineation and opacification, especially in systole, with
OPTISON in this group compared with all patients (Figs. 2–4).
Therefore, the greatest effects of OPTISON were in those
patients in whom contrast echocardiography would have ben-
efited the most. These patients typically have the poorest
quality echocardiograms. One may surmise that the preserva-
tion of bubble size and concentration due to perfluoropropane
in OPTISON resists the destruction of microspheres by ultra-
sound energy in these patients.
Systole versus diastole. It is well known that the contrast
effects of ALBUNEX are significantly reduced during systole
(18). This was observed in the present study (Figs. 2–4). While
this phenomenon has been actively investigated, the precise
mechanism has not been clearly defined. Microsphere destruc-
tion or compression during the high LV pressures of systole
have been implicated (18–20). The contrast effect of OPTI-
SON did decrease somewhat during systole in the present trial
Table 2. Side Effects Considered to Be Agent Related









Transient altered taste 4 (2%) 4 (2%) 1 (1.4%) 1 (1.4%)
Flushing/warmth 4 (2%) 2 (1%) 0 1 (1.4%)
Nausea 0 2 (1%) 0 1 (1.4%)
Headache 1 (0.5%) 0 0 0
Injection site pain 1 (0.5%) 1 (0.5%) 0 1 (1.4%)
Dry mouth 0 1 (0.5%) 0 0
Ecchymosis at intravenous site 0 1 (0.5%) 0 0
Data are numbers of patients.
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but to a much lesser extent than ALBUNEX (Figs. 2–4). The
higher concentration of microspheres delivered to the left
ventricle must in some way counteract the effects of systolic
pressures (14).
Side effects. The side effects of ALBUNEX have been well
studied (2–5). Altered taste sensation has been the most
common symptom. Similar side effects were noted with AL-
BUNEX in the present study. In this and in previous studies,
side effects were mild, transient, and required no treatment (2–5).
The absence of significant side effects with ALBUNEX may be
due, in part, to its lack of hemodynamic alterations. In several
studies, ALBUNEX did not change right- and left-sided cardiac
pressures, LV contractility, or blood gases (13,17,21).
In the present investigation, the side effects observed with
OPTISON were similar and occurred with the same frequency
as with ALBUNEX. All were mild and resolved spontaneously.
OPTISON was also well tolerated in another study of patients
with coronary artery disease (6). As with ALBUNEX, OPTI-
SON has been shown not to alter pulmonary and left heart
pressures, LV contractility, myocardial blood flow, and blood
gases (7,21,22). In the subgroup of patients in our study with
pulmonary and/or cardiac dysfunction, the frequency of side
effects was low. This observation is particularly important
because of the theoretical concern that these patients are
prone to pulmonary microcirculatory embarrassment after
injection of microspheres. In fact, some studies of ultrasound
contrast agents under development have specifically avoided
patients with pulmonary disease (23). We conclude that the
safety profile of OPTISON is excellent and equivalent to that
of ALBUNEX.
Limitations of study. The true duration of OPTISON was
underestimated in this study. Investigators were not specifically
asked to determine its actual duration. When protocol imaging
was complete, no further evaluations were made, even though
OPTISON was still present on the echocardiogram. Neither
harmonic nor intermittent imaging was employed. These tech-
niques have been shown to enhance the contrast effects of
ultrasound contrast agents and have great promise for the
future (24,25).
Conclusions. OPTISON is an excellent contrast agent that
is superior to ALBUNEX for LV endocardial border delinea-
tion and opacification. The safety profile of OPTISON is equal
to that of ALBUNEX in both a general population of patients
and in those with cardiac and/or pulmonary dysfunction.
We are indebted to Mrs. Tracy Banks for her secretarial assistance.
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